MONOClonAL ANTIBOdY CLINICAL PATHWAY FOR COVID-POSITIVE PATIENTS

COVID Positive Patient
≥12 years old, ≥88 lb.

Need Hospitalization?

YES – (Severe symptoms)
Admit to hospital with consideration for Remdesivir

NO – (Mild to moderate symptoms)
Candidate for monoclonal antibody Casirivimab/Imdevimab or Sotorovimab

Criteria for further consideration:
BMI ≥ 25 or 85 percentile
Sickle Cell Disease
Cardiovascular Disease or Hypertension
Chronic Lung Disease (Asthma, COPD, others)
Pregnancy
Chronic Kidney Disease

Diabetes
Immunosuppression
Neurodevelopment disorders
Medical-related technologic dependence
≥65 years of age
Patient benefits outweigh risks

YES
Outpatient infusion of available and appropriate COVID antibody
Inform patient that COVID-19 vaccination should be deferred for at least 90 days to avoid interference of the treatment with vaccine-induced immune responses

NO
Close monitoring of condition
Administration is not restricted to the list of conditions outlined above. Providers should consider benefit to risk ratio when considering this treatment for patients (i.e. race/ethnicity, social situation, etc.)

If you have any additional questions, concerns, and/or need further guidance with ordering therapies or referring patients contact the NDDoH Department of Operations Center (DOC) at (701) 328-0707.

Revised: 08/08/2021